A carregar...
Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
BACKGROUND: A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Patients with advanced HCC and Child–Pugh score ≤7 received pasireotide LAR 60 mg intramuscularly every 28 days. Primary endpoin...
Na minha lista:
| Publicado no: | J Hepatocell Carcinoma |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5769585/ https://ncbi.nlm.nih.gov/pubmed/29392123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JHC.S153672 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|